Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Модуляция врождённого и адаптивного иммунитета с помощью (R)-росковитина: потенциальная терапевтическая возможность при муковисцидозе
2016-01-01
SCID: 54.1/832y4q4k
Discuss with AI
(R)-RoscovitineCystic fibrosisF508del-CFTR traffickingInnate and adaptive immunityTRPC6 ion channel
Figures from the paper
Abstract (AI)
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammatory lymphocytes and reduced production of various interleukins, notably IL-17A) contribute to the resolution of inflammation and restoration of innate immunity, and (4) roscovitine displays analgesic properties in animal pain models. The fact that (R)-roscovitine has undergone extensive preclinical safety/pharmacology studies, and phase I and II clinical trials in cancer patients, encourages its repurposing as a CF drug candidate.
Key Findings
1
(R)-Roscovitine combines four properties potentially beneficial for cystic fibrosis: CFTR rescue, macrophage antibacterial restoration, anti-inflammatory immunomodulation, and analgesia.
2
By increasing TRPC6 membrane targeting, (R)-roscovitine restores phagolysosomal acidification and bactericidal activity in CF alveolar macrophages.
3
It promotes neutrophil and eosinophil apoptosis, inhibits eosinophil degranulation, and shifts Th17/Treg balance toward anti-inflammatory lymphocytes with reduced interleukin production, notably IL-17A.
4
Prior extensive preclinical studies and phase I–II cancer trials support repurposing (R)-roscovitine as a cystic fibrosis drug candidate, although the abstract presents it as a potential opportunity rather than established therapy.
5
The compound partially protects F508del-CFTR from proteolytic degradation and promotes its trafficking to the plasma membrane.
Research Object
(R)-Roscovitine as a therapeutic agent for cystic fibrosis
Research Subject
The therapeutic effects and mechanisms of (R)-roscovitine on CFTR trafficking, phagolysosomal acidification, antimicrobial activity, immune-cell function, inflammation, and pain
Publication Details
Publication Date
2016-01-01
Journal
Publisher
ISSN
Cited by
4992
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by9
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)2016
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya2018
Targeting fibrosis: mechanisms and clinical trials2022
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine2020
Neutrophil Extracellular Traps Participate in Cardiovascular Diseases2020
Physiology and pathophysiology of human airway mucus2022
Therapeutic advances of targeting receptor tyrosine kinases in cancer2024
A review of cystic fibrosis: Basic and clinical aspects2021
Optimized DNA electroporation for primary human T cell engineering2018